DOT Drug Testing Numbers - What the Data Is Not Telling You
- Ray Hubert
- 1 day ago
- 8 min read
Here is the number that should stop the conversation cold: as of this January, more than 200,000 commercial drivers were sitting in `prohibited status` in the FMCSA Clearinghouse. They were barred from getting behind the wheel of a commercial motor vehicle.
Roughly 159,000 of them had not even started the process required to return to duty.
That is not a rounding error. That is a parked workforce the size of a mid-sized city.
The problem is that most headlines about drug testing blur two very different worlds: the general U.S. workforce and the DOT-regulated workforce. Those are not the same. A failed pre-employment test at a retail job is serious. A failed test by a truck driver, pilot, transit operator, pipeline worker, railroad employee, or maritime worker carries a different public safety weight.
The public numbers tell part of the story. The missing context tells the rest.
The broader workforce numbers set the stage
Before looking at DOT-specific testing, the broader U.S. workforce matters because it reflects the environment employers operate in.
Quest Diagnostics’ 2025 Drug Testing Index, one of the industry’s major benchmarks, reported that combined hair-test positivity reached 19.1%, up from 13.1% in just over four years. That is a 46% increase.
Urine testing looked much flatter, holding around 4.3%.
That gap matters. Hair and urine testing measure different windows of use. A urine test is more likely to catch recent use. Hair testing can reflect a longer pattern. So when hair positivity rises sharply while urine positivity stays mostly steady, it does not give one simple answer. It may point to more recurring use, different detection windows, changing employer testing choices, or all of the above.
Marijuana remains the biggest driver in the general workforce data. It appears in just over half of all positive hair tests. Other substances are rising too:
Cocaine positivity is up 48% since 2021.
Methamphetamine positivity is up 19%.
Amphetamines are up nearly 28%.
Fentanyl positivity fell year over year to 0.28%.
That fentanyl number needs careful reading. Fentanyl is not part of the standard DOT drug testing panel. In many workplace programs, it is an add-on test. That means the reported positivity may not fully reflect actual use across all workers.
Industry comparisons also need context. Quest reported healthcare with the highest overall positivity among tracked industries, at 5.8%. Retail had the highest marijuana-specific positivity, at 7.6%. Manufacturing and transportation/warehousing came in lower, at 4.2% each.
That last transportation number can sound reassuring. It should not be read as a clean proxy for DOT safety-sensitive workers.
Transportation and warehousing is a broad category. It includes many workers who are not subject to DOT drug and alcohol testing rules. Warehouse staff, dispatch support, non-CDL delivery roles, logistics employees, and many others can sit inside that same bucket.
DOT testing is narrower and more consequential. It is built around safety-sensitive duties.
DOT testing is not one workforce
The phrase “DOT drug testing” sounds like one program. In practice, it covers several industries, each with different risk profiles, staffing models, and public reporting systems.
DOT testing rules are set forth in 49 CFR Part 40, which establishes procedures for HOW the testing is conducted. The agencies then establish the WHEN the testing is done.
The main groups include:
Agency data on violations and return-to-duty | Covered workforce | What makes the data different |
FMCSA 49 CFR Part 382 | Commercial motor vehicle drivers | The Clearinghouse creates unusually visible data on violations and return-to-duty. |
FAA 14 CFR Part 120 | Safety-sensitive aviation workers | Testing covers roles such as flight crew, mechanics, dispatchers, and others, but public visibility is less direct. |
FTA 49 CFR Part 655 | Transit workers | Public transportation includes operators, maintenance roles, and control functions tied to passenger safety. |
FRA 49 CFR Part 219 | Railroad employees | Rail testing includes covered service roles in which impairment can pose a major public risk. |
PHMSA 49 CFR Part 199 | Pipeline workers | The workforce is smaller, but incidents can have high environmental and public safety consequences. |
USCG 46 CFR Part 4 & 16 | Maritime workers | Testing applies to certain marine safety-sensitive positions, with its own operating realities. |
The mistake is treating these agency numbers as interchangeable.
A 1% rate in one mode does not mean the same as a 1% rate in another mode. A small agency population can show sharp percentage swings with relatively few positives. A large workforce can absorb thousands of violations, even if the percentage appears modest. Pre-employment testing also tells a different story from random, post-accident, reasonable suspicion, or return-to-duty testing.
The headline rate is usually the least interesting number.
FMCSA is the clearest warning signal
The FMCSA Clearinghouse changed the conversation by making driver violations much harder to hide.
Before the Clearinghouse, a driver with a violation could sometimes move between employers without the next carrier seeing the full picture. The Clearinghouse created a centralized record for CDL and CLP holders covered by FMCSA drug and alcohol testing rules.
The current prohibited-status number tells two stories at once.
First, the system is catching violations and keeping drivers out of safety-sensitive work until they complete the required return-to-duty process. That is the public safety purpose.
Second, an enormous share of drivers are not coming back.
If more than 200,000 drivers are prohibited and roughly 159,000 have not started the return-to-duty process, then the issue is not only testing positivity. It is also workforce disengagement after a violation.
To return, a driver generally must:
Meet with a qualified Substance Abuse Professional, known as a SAP.
Complete the SAP’s recommended education or treatment plan.
Be found eligible for return-to-duty testing.
Take and pass a directly observed return-to-duty test.
Complete a follow-up testing plan after returning to safety-sensitive work.
That process is not instant. It costs money. It requires time, accountability, and employer participation. Some drivers may not understand the steps. Some may leave the industry. Some may be unable or unwilling to stop using a prohibited substance. Some may face barriers finding a SAP or an employer willing to take them back.
The big number tells us who is parked. It does not tell us why.
Marijuana is still the hardest policy problem
Marijuana sits at the center of the DOT testing debate because state law and federal rules point in different directions.
Many states allow medical or recreational marijuana. DOT safety rules do not. Marijuana remains prohibited for DOT safety-sensitive workers, and a medical marijuana card does not excuse a positive DOT test.
That creates confusion, especially for employees who use marijuana legally under state law while off duty.
The testing science adds another layer. A positive marijuana test does not prove impairment at the exact moment of testing. It shows prohibited drug use based on the federal testing standard. For DOT programs, that distinction does not change the outcome. A verified positive test is still a violation.
This is one of the biggest things the public numbers do not explain. Positivity data can show how often marijuana is detected. It cannot show:
Whether the person was impaired while working.
Whether use was occasional or frequent.
Whether the worker understood the DOT rule.
Whether state legalization affected risk perception.
Whether the employer trained clearly on the difference between legal use and DOT compliance.
The result is a policy gap that shows up as a testing problem.
Agency-by-agency data leaves too many blind spots
DOT agency reports are useful, but they are not always easy to compare. Each mode reports through its own systems and time frames. Some data is summarized in management information system reports. Some is easier to access than others. Some is published in ways that make trend analysis difficult for anyone outside the compliance world.
That does not mean the data is bad. It means the data is incomplete for the questions people actually ask.
The questions tend to be simple:
Are safety-sensitive workers using more drugs than before?
Which substances are driving violations?
Are random tests finding the problem, or mostly pre-employment tests?
How many workers return safely after a violation?
How many leave the industry?
Are small operators struggling more than large operators?
Are education and treatment steps working?
The available numbers often answer narrower questions:
How many tests were conducted?
How many verified positives occurred?
What was the positivity rate by test type?
How many refusals were reported?
How many workers were removed from duty?
Those are important, but they do not complete the picture.
A random-test positive may signal an active safety concern inside an existing workforce. A pre-employment positive may show that the screening process stopped someone before they entered a role. A post-accident positive raises a different set of questions, though it still does not automatically prove cause.
When all positives get blended together, the public loses the ability to separate prevention from active operational risk.
The missing number is the return rate
The most important drug testing number may not be positivity. It may be return-to-duty completion.
A positive test removes a worker from safety-sensitive duty. That is the immediate safety action. But the long-term question is whether the system helps qualified workers return once they meet the rules, or simply creates a growing pool of people who never come back.
The FMCSA Clearinghouse gives the clearest view of this problem because it tracks prohibited status and return-to-duty progress. Other DOT modes do not give the public the same simple dashboard-style visibility.
That matters because workforce shortages and safety rules often get discussed as if they are enemies. They should not be.
A strong return-to-duty system can support both goals. It keeps impaired workers out of safety-sensitive roles, while creating a controlled path back for those who complete evaluation, education or treatment, testing, and follow-up.
The weak point is the gap between violation and engagement. If a worker never starts the process, the system has removed the immediate risk, but it has not resolved the underlying issue.
That is where employers, consortiums, third-party administrators, medical review officers, SAPs, and regulators all have a role.
What employers should take from the numbers
The data points toward a practical conclusion: compliance alone is not enough.
A company can run every required test, file every required report, and still miss the human and operational patterns behind the results.
Better programs tend to do a few things well:
They explain DOT rules in plain language before a violation happens.
They train supervisors to spot signs that justify reasonable suspicion testing.
They separate state marijuana law from federal DOT rules in every training.
They make the return-to-duty process clear before anyone needs it.
They track test type, substance, timing, and job function internally.
They review refusals with the same seriousness as positive tests.
They avoid treating pre-employment positives and random positives as the same risk signal.
The best question is not only, “Are we compliant?”
A better question is, “Can we see where the risk is forming before it becomes a violation, an accident, or a permanent loss from the workforce?”
The numbers matter, but the gaps matter more
The broad workforce data says drug positivity is rising in important ways, especially when longer detection windows are used. The DOT data says safety-sensitive industries face a more specific challenge. FMCSA’s Clearinghouse shows that violations do not end with a test result. They can remove hundreds of thousands of drivers from the available workforce, and many never begin the path back.
That is what the headline numbers are not telling you.
They show positives, rates, and prohibited status. They do not fully show intent, impairment, education gaps, treatment access, employer follow-through, or the reasons workers walk away after a violation.
The next phase of DOT drug testing should not be a softer system. Public safety depends on firm rules. But the system does need clearer public data, better worker education, and more attention to what happens after someone is removed from duty.
A test can catch a problem. A better program explains the underlying pattern that created the problem in the first place.
Comments